A randomized, open label, phase II proof of concept study of WX-671 in combination with gemcitabine vs. gemcitabine alone in patients with locally advanced, non resectable pancreatic cancer in order to evaluate the anti-tumor activity of the combination therapy.

Trial Profile

A randomized, open label, phase II proof of concept study of WX-671 in combination with gemcitabine vs. gemcitabine alone in patients with locally advanced, non resectable pancreatic cancer in order to evaluate the anti-tumor activity of the combination therapy.

Completed
Phase of Trial: Phase II

Latest Information Update: 14 Feb 2013

At a glance

  • Drugs Upamostat (Primary) ; Gemcitabine
  • Indications Pancreatic cancer
  • Focus Adverse reactions; Biomarker; Proof of concept; Therapeutic Use
  • Most Recent Events

    • 28 Mar 2012 Actual end date (1 May 2010) added as reported by ClinicalTrials.gov.
    • 28 Mar 2012 Company added in association field as reported by ClinicalTrials.gov.
    • 08 Oct 2010 Results presented at the 35th Congress of the European Society for Medical Oncology (ESMO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top